Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis
NCT ID: NCT00667758
Last Updated: 2012-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
104 participants
INTERVENTIONAL
2008-05-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Cetrorelix
Cetrorelix
3-5 mg s.c. on days 1-5
2
NaCl solution
Placebo
3-5 ml NaCl s.c. on days 1-5
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cetrorelix
3-5 mg s.c. on days 1-5
Placebo
3-5 ml NaCl s.c. on days 1-5
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe disease activity
* Negative pregnancy test for women of childbearing potential
* Use of reliable method of contraception (non-hormonal) by sexually active female patients
Exclusion Criteria
* Patients taking biologic therapy or prednisolone \>7.5mg
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Norwegian Foundation for Health and Rehabilitation
OTHER
University of Oslo
OTHER
Betanien Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anita Kass
Dr Anita Kåss
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kåss
Role: PRINCIPAL_INVESTIGATOR
University of Oslo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Deaprtment of Rheumatology, Betanien Hospital
Skien, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kass A, Hollan I, Fagerland MW, Gulseth HC, Torjesen PA, Forre OT. Rapid Anti-Inflammatory Effects of Gonadotropin-Releasing Hormone Antagonism in Rheumatoid Arthritis Patients with High Gonadotropin Levels in the AGRA Trial. PLoS One. 2015 Oct 13;10(10):e0139439. doi: 10.1371/journal.pone.0139439. eCollection 2015.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007/2/0174
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
R1/05
Identifier Type: -
Identifier Source: org_study_id